Skip to main content
micro-community-banner
 
  • Saved

made a Post

Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma - PubMed

doi: 10.1111/ejh.13690. Online ahead of print. 1 Medizinische Klinik, München Klinik Schwabing, Munich, Germany. 2 Asklepios Tumorzentrum Hamburg, AK Altona und AK St. Georg, Hamburg, Germany. 3 Medizinische Klinik und ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34270825/

  • Saved

made a Post

Trying to stomach multiple myeloma: A case report - PubMed

We report a case of a 51-year-old male with minimal past medical history who presented to his primary care provider with nausea, vomiting and constipation in the outpatient setting. Concomitantly, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34123929/

  • Saved

made a Post

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma - PubMed

Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34131635/

  • Saved

made a Post

Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development - PubMed

Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34133718/

  • Saved

made a Post

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma - PubMed

doi: 10.1186/s40364-021-00296-7. 1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. 3 Department of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34134766/

  • Saved

made a Post

Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure? - PubMed

Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34110512/

  • Saved

made a Post

Multiple Myeloma: From Baby Steps to Giant Strides

The past three decades have witnessed major paradigm shifts in the management of multiple myeloma (MM), resulting in significant improvements not only in the survival from the diagnosis but also ..... see more

Source : https://ascopubs.org/doi/10.1200/OP.21.00327

  • Saved

made a Post

Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift

Multiple myeloma (MM) is a genetically heterogenous disease and remains mostly incurable with a small group of patients achieving long-term disease remission. The past decade witnessed enormous efforts to break ..... see more

Source : https://ascopubs.org/doi/full/10.1200/OP.21.00032

  • Saved

made a Post

Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions - PubMed

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34110937/

  • Saved

made a Post

Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP Inhibitor in multiple myeloma - PubMed

Multiple myeloma (MM) is a malignancy of antibody-producing plasma cells with genomic instability and genetic abnormality as its two hallmarks. Therefore, DNA damage is pervasive in MM cells, which indicates ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34111425/

  • Saved

made a Post

Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma - PubMed

Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Nonlinear mixed-effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34076364/

  • Saved

made a Post

Review of Venetoclax in CLL, AML and Multiple Myeloma - PubMed

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34073976/

  • Saved

made a Post

KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells - PubMed

The lysine demethylase KDM2A (also known as JHDM1A or FBXL11) demethylates histone H3 at lysine K36 which lead to epigenetic regulation of cell proliferation and tumorigenesis. However, many biological processes ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079757/

  • Saved

made a Post

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial - PubMed

doi: 10.1186/s12885-021-08325-2. 1 Department of Haematology and Oncology, Würzburg University Medical Center, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. [email protected] 2 University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34078314/

  • Saved

made a Post

Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma - PubMed

doi: 10.1007/s00432-021-03668-6. Online ahead of print. 1 Department of Hematology, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto, Tokushima, 770-8539, Japan. [email protected] 2 Department of Hematology, Gunma University Graduate School of Medicine, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34080068/

  • Saved

made a Post

M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models - PubMed

2021 May 27;molcanther.MCT-21-0005-A.2021. doi: 10.1158/1535-7163.MCT-21-0005. Online ahead of print. 1 Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany [email protected] 2 Merck KGaA. 3 Merck KGaA, Darmstadt, Germany. 4 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34045234/

  • Saved

made a Post

Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma - PubMed

doi: 10.3389/fphar.2021.651523. 1 Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 2 Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3 Fundação Ezequiel Dias, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34045961/

  • Saved

made a Post

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma - PubMed

Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34046363/

  • Saved

made a Post

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2, 3 This may negatively ..... see more

Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17541

  • Saved

made a Post

Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma - PubMed

Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34014671/